The targeted RAS inhibitor therapy daraxonrasib demonstrated the potential to improve patient outcomes over current standard treatments for patients with RAS-mutant pancreatic cancer, according to results of a Phase 1/2 trial led by David Hong, M.D., deputy chair of Investigational Cancer Therapeutics. Thirty-eight patients received a 300 mg. dose of daraxonrasib. The response rate was 29% and median overall survival was 15.6 months, a significant improvement over historical response rates to second-line chemotherapy.
“This trial provides a really strong signal that this targeted therapy has the potential to extend the overall survival of these patients,” Hong said. “We saw rapid and durable responses, and the manageable overall safety profile supports the ongoing evaluation of daraxonrasib.”